Clinical trial · Observational
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
NCT06730412CI-TRIAL-00098463Clear-HPVcacompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Positive Oropharyngeal Squamous Cell Carcinoma | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- HPV-associated head and neck cancer patients treated with surgery
- description
- AJCC 8 Stage I-III HPV+ head and neck cancer patients treated with curative intent surgery
Primary outcomes (2)
- measure
- Disease free survival
- timeFrame
- 2 years
- description
- Disease free survival in patients with versus without minimal residual disease detection after surgery
- measure
- Overall survival
- timeFrame
- 2 years
- description
- Overall survival in patients with versus without minimal residual disease detection after surgery
Secondary outcomes (2)
- measure
- Disease free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Greater than or equal to 18 years of age * Newly diagnosed, untreated, histologically confirmed HPV-associated head and neck cancer * Scheduled for curative intent resection as primary treatment * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Exclusion Criteria: * Not meeting all inclusion criteria * Pregnant * Receiving treatment for concurrent second malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.